Matrix metalloproteinases (MMP) are a family of host-derived enzymes involved in the turnover of extracellular matrix (ECM) molecules, and, in particular, it is demonstrated that the 92 KDa gelatinase MMP-9 is often expressed in atherosclerotic plaques by macrophages and smooth muscle cells. Recent evidence supports a role of Toll-like receptor (TLR) signaling in the development of atherosclerosis lesions. In this study, we analyzed the TLR2/TLR4 expression in HUVEC infected with C. pneumoniae and correlated it to the production of VEGF and MMP-9. The results obtained showed an increased VEGF and MMP-9 production correlated with a time-dependent increase in cellular proliferation in HUVEC infected with C. pneumoniae at a multiplicity of infection (MOl) of 2 IFU/cell. HUVEC preincubated with VEGF antibody did not release MMP-9, as detected by zymography assessment and ELISA assay. In addition, we demonstrated that TLR2/TLR4 are expressed in HUVEC infected with viable microorganisms (25% and 17%, respectively), while UV-inactivated microorganisms induced a lesser expression (20% and 11%, respectively) compared to control cells and HUVEC exposed to heatkilled bacteria showed a percentage of TLR-expressing cells similar to the control cells. In addition, the cells preincubated for 60 min with TLR2/TLR4 neutralizing antibodies showed a decrease in C. pneumoniae-induced VEGF and MMP-9 production.
A number of opportunistic pathogenic organisms including bacteria and fungi can occasionally gain entry into the human cardiovascular system, resulting in acute or chronic complications (1) . Systemic bacterial infections can lead to life-threatening infective endocarditis, disseminated intravascular coagulation or immune thrombocytopenia and are reported to play an important role in the progression of chronic inflammatory diseases including atherosclerosis and coronary artery disease (2, 3) .
Chlamydiae are obligate intracellular pathogens with a specific developmental cycle inside the host cell that have developed unique strategies to promote their intracellular survival (4) . Recent findings have shown that the pathogen is able to modulate host cell signaling pathways to ensure either its replication, as in an acute infection, or its prolonged survival in a host cell prevented from undergoing apoptosis (4) (5) (6) .
Because the pathogen is a common cause of respiratory infection, the alveolar monocytes exposed to or infected with the organism may travel in the bloodstream and enter the atherosclerotic plaque, where they undergo differentiation into macrophages, causing active C.pneumoniae infection (7) . In macrophages, as well as in endothelial cells and smooth muscle cells, C. pneumoniae can spontaneously enter its persistent state and remain indefinitely in this viable but nonproductive form (4) without causing any damage until reactivated by immunosuppression or by coincidental infection with other organisms (8) . C.pneumoniae infection has been implicated as a high risk factor for atherosclerosis, based on in vitro (seroepidemiological) studies and histopathological animal models and limited clinical intervention studies (9, 10) . As the innate immune system constitutes one of the first barriers of the human immune defense, we started by studying the dependency of MMP regulation on the stimulation of an integral component of the innate immune system, the toll-like receptors (TLRs) (11) . TLRs function as important signal transducers that mediate the innate immune and inflammatory responses to pathogens through pattern recognition of virulence molecules (12) . In particular, TLR2 and TLR4 (TLR2/4) were the first members of this innate immune receptor family to be strongly implicated in antibacterial host defense (13) . TLR2 and TLR4 signaling are involved in the development ofboth beneficial and pathophysiological events during the infection process with Chamydiae (13) . Thus, bacterial and viral products may play an important role in the initiation/perpetuation of disease by chronic pathogens by activating the innate immune system (14) .
Several studies suggest that the over-expression of MMPs in atherosclerotic lesions not only modulates the arterial remodeling but also contributes to plaque vulnerability and rupture by degrading extracellular matrix proteins of the fibrous cap (15, 16) .
MMPs comprise a large family of Zn and Cadependent endopeptidases whose capacity to degrade the extracellular matrix is associated with tissue remodeling, chronic inflammation, the progression of various infectious diseases and the participation in various aspects of the immune response (17) (18) (19) . Over-expression ofmembers ofthe matrix degrading MMP family in pathological conditions characterized by connective tissue destruction, as seen in diseases such as arthritis, atherosclerosis, periodontitis and cancer, suggested that the regulation of MMP genes is critical for normal tissue homeostasis (20) . Since the previous studies did not determine how TLR ligands regulate the balanced expression .of metalloproteinases in chlamydial infection (14) , in this work we studied whether C. pneumoniae activates TLR2/TLR4 and if this activation brings about the release of MMP-9 and VEGF in human vascular endothelial cells.
MATERIALS AND METHODS

Cell lines
Human umbilical vein endothelial cells (HUVEC) were obtained from Cell Applications, Inc. (San Diego, CA, USA), and were cultured in endothelial cell growth medium (ECGM) supplemented with 2% fetal bovine serum (FSB). Cultures were maintained in a humidified 5% CO 2 atmosphere at 37°C.
C. pneumoniae strain
C. pneumoniae (AR39) was propagated in HEp-2 cell monolayers, as described by Roblin (21) . In brief, C. pneumoniae was inoculated onto a pre-formed monolayer of HEp-2 cells in 35mm-diameter wells, centrifuged at 1000 x g for 60 min at 25°C and incubated at 37°C with 5% CO 2 for 60 min. Supernatants were replaced with growth medium consisting of RPMI 1640 containing 1 ug ml' of cycloheximide. Infected cultures were incubated from 24 to 72 h at 37°C in 5% CO 2 • C. pneumoniae was harvested by disrupting HEp-2 cells with glass beads followed by sonication and centrifugation at 25.0 x g to remove cellular debris. For some experiments, supernatants containing C. pneumoniae were further centrifuged at 20,000 x g for 20 min to pellet elementary bodies (EBs). The EBs pellet was then suspended in sucrose-phosphate-glutamate buffer, aliquoted and stored at -70°C. Infectivity titers of chlamydial stocks were quantified by titering the inclusion-forming units (IFU) per milliliter In HEp-2 cells. These titers were used to determine the infectious doses for the cell lines studied. Cell cultures and chlamydial stocks were confirmed to be free of Mycoplasma infections using 4, 6-diaminodino-2phenylindole (DAPI) fluorescent staining (Sigma-Aldrich S.r.l. Milan, Italy). Contamination with Mycoplasma was also excluded by Mycoplasma PCR using specific primers (MWG Biotech, Martinsried, Germany).
Infection ofHUVEC with C.pneumoniae
For infection, HUVEC were seeded in 24-well dishes and incubated for 24 h in 5% CO 2 at 37°C. The media were removed 4 h before infection and culture media without antibiotics were added to allow bacterial growth. The cells were then infected with C. pneumoniae by centrifugation at 1000 <g for 60 min at a multiplicity of infection (MOl) of2 IFU/cell (a preliminary study showed this MOl to be the optimum rate) and incubated for 24, 48 and 72 h. In addition to infection with viable C.pneumoniae, HUVEC were stimulated with organisms that had been previously heat-inactivated (90°.C for 30 min) or UV-inactivated by UV lamp (l5W at 30 em) for 15 min. The cells were collected for flow cytometry assay, and the supernatants for the enzyme-linked immunosorbent assay (ELISA) and gelatin zymography were frozen at -80°C until use. For some experiments, HUVEC were treated with 250ng/ml anti-human VEGF antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or lOng/ml recombinant human VEGF (rhVEGF) (Sigma-Aldrich S.r.l. MI,USA) for 60 min and then infected with C. pneumoniae (MOI=2).
To monitor that HUVEC are capable of supporting the growth of C. pneumoniae in vitro, 48 h post-incubation the infected cells were fixed with 100% methanol and stained for the inclusion bodies using an FITC-conjugated anti-major outer membrane protein (MOMP) monoclonal antibody (DakoCytomation S.p.a. Milan, Italy). The samples were examined at a magnification of x400 by confocal fluorescence microscopy (AxIOSKop2 ZEISS).
ELISA assay
To determine MMP-2 and MMP-9 protein expression and VEGF levels in supernatants from C. pneumoniaeinfected HUVEC, the supernatants were collected and assayed by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's directions (R&D Systems). Concentrations were calculated from the standard curve produced for each plate.
HUVEC proliferation assay
To determine the proliferative properties of HUVEC to C. pneumoniae infection, the HUVEC were seeded at 10 5 cells/well and infected with C. pneumoniae at MOI=2 for 24, 48 and 72 h. The number of living cells was determined by a colorimetric enzyme assay (CellTiter 96 Cell Proliferation Assay. Promega Corporation) based on the cytoplasmic enzyme activity present in viable cells. The absorbance of a formazan product in tissue culture media was measured at 500 om using a microplate reader. The cells were then harvested and counted with a hemacytometer; proliferation was calculated as the number ofcells harvested/number of cells seeded. Control HUVEC were grown in medium or medium containing 10 ng of recombinant human VEGF (rhVEGF)/ml.
Gelatin zymography
To evaluate the effect of C. pneumoniae infection on MMP-2 and MMP-9 secretion in HUVEC, 4xl0 5 cells were plated in 6-well plates (35 mm diameter). The gelatinolytic activity of MMP-2 and MMP-9 was determined with the method of Heussen and Dowdle (22) adapted for a minigel format. Conditioned media of each sample were centrifuged at 6000 rpm for 20 min and the protein content of the supernatant was estimated by Bradford's method. Twenty micrograms of sample were mixed with an equal volume of 2x non-reducing sample buffer and each sample was separated by 10% (w/v) polyacrylamide gel containing 2mg/ml ofgelatin (Sigma). After electrophoresis, the gel was incubated in 2.5% of Triton X-100 for I h to remove SDS and then overnight at 37°C in the developing buffer (50 mM of Tris-HCl, pH 7.6, containing 0.2 M NaCI, 5 mM of csci, and 0.02% (w/v) Brij-35). The gel was stained for 45 min in 40% methanol/l0% glacial acetic acid containing 0.1% (w/v) Coomassie Brilliant Blue R 250 and de-stained in the same solution without Coomassie Brilliant Blue. MMP-2 and MMP-9 activity were quantified by densitometric scanning of the zymographic bands.
Immunofluorescence for TLR2/TLR4
Flow cytometric analysis of surface TLR2/TLR4 expression was performed 24, 48 and 72 h post infection with C.pneumoniae at MOI=2 in HUVEC. Approximately Ixl0 6 non-permeabilized cells treated and untreated with C. pneumoniae were blocked with 5% normal mouse serum (Sigma, St. Louis, Mo. USA), stained with the murine anti-human TLR4 antibody (MAb) (HTAI25) (Imgenix, San Diego, USA) or the murine anti-human TLR2 MAb (TL2.1) (Imgenix, San Diego, USA) and labeled with fluorescein isothiocyanate (FITC; Santa Cruz), according to the manufacturer's instructions, and then analyzed using a FACS flow cytometer (Becton-Dickinson). A phycoerythrin (PE)-labeled rat IgG2a MAb (BD, Biosciences) was used as the isotype control for the rat anti-human TLR2/TLR4 antibodies.
TLR2/TLR4 blocking experiments
For blocking experiments, cultured HUVEC were grown on six-well plates and pre-treated with..nf;:UtIalizing anti-human TLR2/TLR4 MAbs or isoc ontrol-purifiedmouse IgG2a MAbs (10 J.1g ml' SantaCrui Biotechnology, CA, USA) for 60 min and then stimulated for 24 to 72 h with C.pneumoniae. The culture media were collected and analyzed for MMPs and VEGF by ELISA. 
Statistical analysis
ELISA assay
Culture supernatants from infected and uninfected cells were analyzed by ELISA for MMP-2 and MMP-9-proteins. The results revealed that in HUVEC infected with C. pneumoniae the gene induction was associated to a significant increase in the levels of MMP-9 protein, but not MMP-2, compared to uninfected cells (control cells) ( Fig. 3, C and D) . In agreement with the time course of zymography, C. pneumoniae induced a slight MMP-9 protein release at 24 h post infection (1100±5.75 pg/ml) and an increase Production of MMP-2 and MMP-9 by infected HUVEC Gelatin zymography HUVEC were infected with C. pneumoniae at MOl =2 and the effect of C. pneumoniae on their ability to secrete 72-kDa gelatinase (MMP-2) and 92-kDa gelatinase (MMP-9) was studied. Fig. 3, A and B show that the cells spontaneously released a small amount of MMP-2 and MMP-9; C. pneumoniae induced a significant zone lysis of MMP-9 on gelatin zymography in a time-dependent manner. In particular, the zymographic assessment of gelatinolytic activity of MMP-9 showed a light expression at 24 h post infection and a peak at 48 h compared to uninfected cells; no further increase was observed between 48 and 72 h of infection (Fig. 3A) . In contrast to MMP-9 expression, C. pneumoniae bacteria did not induce a significant expression of MMP-2 in HUVEC compared to uninfected cells at any time point tested (Fig. 3 B) .
VEGF production in host cells, we infected HUVEC with C. pneumoniae and determined VEGF levels in culture supernatant by ELISA. HUVEC infected with viable C. pneumoniae produced significant levels ofVEGF compared to uninfected cells, with a maximum peak after 48 h of cultivation (1550±6.27 pg/ml vs 543±4.3l pg/ml); no further increase was observed between 48 and 72 h of infection (Fig.  2) . The cells treated for 48 h with UV-treated C. pneumoniae also showed VEGF production albeit at lower concentrations compared to viable C. pneumoniae (l200±5.57 pg/ml); on the contrary, the cells treated with heat-killed C. pneumoniae for 48 h did not show a significant release of VEGF (750±5.12 pg/ml). 
VEGF induction in HUVEC infected with C. pneumoniae
To investigate whether C. pneumoniae can trigger induced MMP production was VEGF-dependent. Recombinant VEGF significantly upregulated the MMP-9 levels (Fig. 4A) and, more importantly, the gelatinolytic activity (Fig. 4B ). Furthermore, HUVEC preincubated with VEGF antibody for 60 min followed by infection for 48 h with C. pneumoniae resulted in a significant downregulation of MMP-9 secretion and gelatinolytic activity (Fig.  4,AandB) .
HUVEC proliferation
To show that infection of HUVEC with C. pneumoniae leads to the production of biologically active VEGF, we cultured HUVEC with C. pneumoniae at MOI=2. The results shown in Table  I indicate that C. pneumoniae-infected HUVEC (A) or treated with rhVEGF (B) exerted proliferation compared to the control cells (C) (4.5±0.64 and 5.7±0.25 vs 3.9±0.35, respectively), On the contrary, C. pneumoniae-infected HUVEC pretreated with anti-human VEGF antibody (D) did not induce a significantly different VEGF expression compared to uninfected cells (4.0±0.12 vs 3.9±0.35, respectively).
Role of VEGF in C. pneumoniae-induced MMP-9 production
Given that VEGF is a known regulator ofMMPs, we sought to determine whether C. pneumoniae- 
C. pneumoniae increases TLR2/TLR4 expression in HUVEC
To begin to determine the in-vitro effects of C. pneumoniae on cell surface TLR2/TLR4 expression, we utilized a human endothelial cell line. Nonpenneabilized cells were exposed to viable bacteria prior to analysis of cell surface TLR2/TLR4 by flow cytometry. As shown in Fig. 5 , HUVEC exposed to C. pneumoniae at MOI=2 for 24,48 and 72 h showed an increase in fluorescence attributable to cell surface TLR2. The cell-surface TLR2 expression at 24 h was of little significance for HUVEC (8%) compared to controls (2.5%). A greater expression of TLR2 was observed in HUVEC after 48 h of infection (25%); the cells exposed to UV-inactivated bacteria also showed a significant expression of TLR2 (20%) compared to control cells; when HUVEC were exposed to heat-killed bacteria, the percentage of TLR-expressing cells was about 6%, similar to the control (4%). No further significant variation was seen for the longer time of infection (72 h; Fig.  5A ). Similarly, bacterial specification significantly influenced TLR4 gene expression in HUVEC after 48 h, although to a lesser degree compared to TLR2 . 5B ). 5 5 The HUVEC response to C. pneumoniae is TLR2/ TLR4-dependent To study the role of TLR2/TLR4 on C. pneumoniae-induced MMP-9 and VEGF, the cells were preincubated for 60 min with TLR2/ TLR4 neutralizing antibodies or an IgG2a isotype control antibody and then stimulated for 48 h with C. pneumoniae at MOI=2. Pretreatment with anti-TLR2/TLR4 antibody, 'but not isotype control antibody, inhibited the amount ofVEGF and MMP-9 in HUVEC incubated with C.pneumoniae compared to the control cells (infected but untreated cells) (Fig. 6, A and B) . These results imply that TLR2 and TLR4 are involved in the significant secretion of both VEGF and MMP-9 in HUVEC stimulated with C. pneumoniae compared to infected but untreated cells (Fig. 6, A and B) . 
DISCUSSION
Disregulated angiogenesis is involved in conditions such as ischemia, heart disease, diabetes and chronic inflammation, including atherosclerosis, and involves the VEGF-MMP system (23) . VEGF is the most important mitogenic and survival factor for vascular endothelial cells (24) . In-vitro assays show the various steps in angiogenesis, including degradation of the extracellular matrix surrounding the parent vessel and migration and proliferation of the endothelial cells and mural cells to assemble the new vessel (24) . In this study, we demonstrate that C. pneumoniae-infected HUVEC induced VEGF production and secretion in a manner dependent on the time of infection, since media harvested at 48 h post-infection had greater mitogenic activity than medium harvested at a shorter time. In addition, by zymographic analysis we showed that C.pneumoniae induced MMP-9 production and gelatinolytic activity in HUVEC. Both VEGF and MMP-9 playa critical role in the initiation and progression of vascular pathologies (25) . MMPs have been implicated in the pathogenesis of chlamydial infections because they are considered classic matrix-remodeling enzymes, and the long-term sequelae of these infections are primarily the result of scar tissue formation (26) . We also demonstrated that when HUVEC were preincubated with inhibitors of VEGF, C. pneumoniae-induced MMP expression and gelatinolytic activity were significantly reduced, supporting the involvement of these pathways in MMP induction. Likewise, by blocking VEGF production this inhibitor decreased C. pneumoniaeinduced HUVEC proliferation. Hence, our result on the C. pneumoniae up-regulation of VEGF with a concurrent increase in MMP-9 suggests a potential causal relationship between C. pneumoniae-induced MMP activity and angiogenesis. In C. pneumoniaetreated cells the production of VEGF and MMP-9 progressively increased with the progression of culture, reaching a maximum at 48 h. This might suggest that the MMP expression is well regulated during the angiogenic process and the process itself regulates its expression, which is suggested by our observation that inhibition of the angiogenic process by anti-VEGF disrupts the regulation ofMMP-9.
An increased expression ofMMP-9 in both active disease and chlamydial infection is of particular interest and may provide a mechanism whereby inflammation and ECM breakdown selfperpetuate in the absence of infection and may therefore have an important role in the development of atherosclerosis.
The results observed also showed that UVinactivated Chlamydia was still able to induce MMP-9 expression, albeit at lower levels, whereas heatkilled C. pneumoniae did not induce a significantly different VEGF or MMP-9 production.
Molecular components of C. pneumoniae that can activate cells include the heat-labile chlamydial membrane compounds, major outer membrane proteins and heat shock proteins or other as yet unidentified virulence factors (27) .
C. pneumoniae-induced host cell activation and reprogramming is a complex mechanism that involves signaling pathways and several receptor systems of the host cells (4). Using a sensitive flow cytometric technique, we found an increased TLR2/ TLR4 expression on the cell surface of HUVEC. It has been reported that TLR2 and TLR4 are essential mediators of C. pneumoniae-related host cell activation and defense (28) . We demonstrated in this study that the induction ofVEGF and MMP-9 by C. pneumoniae appears to be mediated in a predominant manner by a TLR2 pathway, as its production is inhibited by anti-TLR2 blocking, thus confirming the role oftransmembrane TLRs in cellular activation by microbial pathogens.
Other studies have indicated a proatherogenic effect of local TLR2 activation (29) and established a clear role for TLR2 in modulating the severity of experimental atherosclerosis in mice, where complete loss of TLR2 resulted in a decreased lesion size and systemic exposure to an exogenous TLR2 agonist dramatically exacerbated atherosclerosis (30) .
Increased production ofMMP-9 in atherosclerosis may contribute to the matrix destruction that leads to plaque rupture. Immunostaining has shown that in both unstable and stable angina, MMP-9 production in the arteries is elevated, whereas in normal arteries it is not expressed (8) .
In conclusion, the present study clearly demonstrates that C. pneumoniae infection induces VEGF and MMP-9secretion by vascular endothelial cells. Our findings suggest a functional interplay between C.pneumoniae and proangiogenic molecules via multiple signaling including TLR2/TLR4. Given that there is no effective vaccine available for C. pneumoniae, a greater understanding of the complex immunological and molecular mechanisms mediated by the TLRs may allow these molecules to be exploited for successful vaccination strategies.
